文献速递睡眠呼吸障碍肺栓塞与肺血管病

卒中后中枢性睡眠呼吸暂停:患病率、机制与临床意义

Central Sleep Apnea After Stroke: Prevalence, Mechanisms, and Clinical Implications.
PubMed 文献 · Chest · 2026-09-20

该综述聚焦卒中后中枢性睡眠呼吸暂停(CSA)和Cheyne-Stokes呼吸(CSR),指出其患病率在单项研究中差异大(1%-72%),荟萃分析汇总约7%-12%。病理生理涉及神经源性与非神经源性多重机制,作为卒中复发或长期结局的危险因素证据有限且不确定,管理推荐尚不明确。

要点

  • 卒中后CSA/CSR单项研究患病率1%-72%,荟萃分析汇总约7%-12%。
  • CSA可能既是生理应激中介,也是脑、睡眠和心血管易损性的标志。
  • CSA作为卒中复发或长期结局危险因素的证据有限且不确定。

核心结论

  • 卒中后CSA常见、病理生理复杂且治疗探索不足。
  • 需要标准化定义、纵向表型分析、性别特异性分析及超越呼吸暂停低通气指数的生理指标。

研究设计与样本

  • 综述类文章,检索范围未明确报告。

主要发现

  • 卒中后CSA和CSR单项研究报告患病率1%-72%,荟萃分析汇总估计约7%-12%。
  • 纵向数据显示部分患者CSA和CSR改善,反映急性损伤成分,但另一些患者持续存在,提示持续性通气不稳定。
  • CSA病理生理特征为多因素,包括神经源性(中枢自主与呼吸网络破坏、CO2敏感性改变、病灶部位)和非神经源性(心功能障碍、药物、睡眠片段化)机制。
  • CSA作为卒中复发或长期结局危险因素的证据有限且不确定。
  • 少数报告建议观察等待或基于症状的正压通气试验,但诊断、最佳时机和治疗策略推荐仍不明确。

关键数值与推荐

  • 卒中后CSA和CSR单项研究患病率范围1%-72%。
  • 荟萃分析汇总患病率估计约7%-12%。

临床怎么用

  • 临床应识别卒中后CSA和CSR,因其常见但易被忽视。
  • 管理决策需考虑CSA可能反映急性损伤与持续通气不稳定两种情况。
  • 正压通气试验可基于症状考虑,但 optimal 时机和策略尚无明确推荐。

局限性

  • CSA作为卒中复发或长期结局危险因素的证据有限且不确定。
  • 诊断、最佳时机和治疗策略推荐不明确。
  • 需要标准化定义、纵向表型分析、性别特异性分析和超越呼吸暂停低通气指数的生理指标。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

TOPIC IMPORTANCE: Central sleep apnea (CSA) and Cheyne-Stokes respiration (CSR) are common but underrecognized forms of sleep-disordered breathing after stroke. Although OSA dominates poststroke research, CSA and CSR are neglected because they rarely appear in isolation. REVIEW FINDINGS: The reported prevalence of CSA and CSR after stroke shows substantial variability across individual studies (1%-72%), whereas meta-analyses suggest pooled estimates of approximately 7% to 12%. Longitudinal data suggest that CSA and CSR improve in some patients, reflecting a component of an acute injury, yet persist in others, indicating sustained ventilatory instability. CSA may act both as a mediator of physiologic stress and as a marker of cerebral, sleep, and cardiovascular vulnerability. Its pathophysiologic characteristics are multifactorial, combining neurogenic (eg, disruption of central autonomic and respiratory networks, altered CO2 sensitivity, and lesion topography) and nonneurogenic (eg, cardiac dysfunction, medication, and sleep fragmentation) mechanisms. Evidence of CSA as a risk factor for stroke recurrence or long-term outcomes is limited and inconclusive. Although few reports suggested watchful waiting or symptom-based positive airway pressure trials, recommendations on management including diagnostics, optimal timing, and treatment strategies remain unclear. SUMMARY: CSA after stroke is prevalent, pathophysiologically complex, and therapeutically underexplored. A need exists for standardized definitions, longitudinal phenotyping, sex-specific analyses, and physiologic metrics beyond the apnea-hypopnea index to inform better individualized, mechanism-based care for CSA in stroke survivors.

来源:Chest,查看原文。版权归原作者所有。

引用

  1. Brill AK, Horvath CM, Baillieul S, et al. Central Sleep Apnea After Stroke: Prevalence, Mechanisms, and Clinical Implications. Chest. 2026. PMID: 42764103. doi:10.1016/j.chest.2026.09.015

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。